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Abstract
MicroRNAs play extensive roles in cellular development. Analysis of the microRNA expression pattern during intestinal cell
proliferation in early life is likely to unravel molecular mechanisms behind intestinal development and have implications for
therapeutic intervention. In this study, we isolated mouse intestinal crypt cells, examined the differences in microRNA
expression upon IGF-1 stimulated proliferation and identified miR-103 as a one of the key regulators. Mouse intestinal crypt
cells were cultured and treated with IGF-1 for 24 h. MicroRNA microarray showed that multiple microRNAs are regulated by
IGF-1, and miR-103 was the most sharply down-regulated. Expression of miR-103 in mouse intestinal crypt cells was
confirmed by real-time Q-PCR. Sequence analyses showed that, among the 1040 predicted miR-103 target genes, CCNE1,
CDK2, and CREB1 contain complementary sequences to the miR-103 seed region that are conserved between human and
mouse. We further demonstrated that miR-103 controls the expression level of these three genes in mouse crypt cells by
luciferase assay and immunoblotting assay. Taken together, our data suggest that in mouse intestinal crypt cells, miR-103 is
part of the G1/S transition regulatory network, which targets CCNE1, CDK2, and CREB1 during IGF-1 stimulated proliferation.
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Introduction
The small intestinal epithelium is a major site for nutrient
absorption and also serves as an important barrier to prevent
exogenous pathogens from entering the body. The small intestine is
also a highly dynamic and well-structured tissue which compart-
mentalizes into villi and the crypts of Lieberkuhn (crypts). The
intestine regenerates itself throughout the life as the intestinal
epithelial cells regularly shed off from the villi. This continuous cell
renewal process is achieved by pluripotent epithelial stem cells
which populate the specialized proliferative units known as the
crypts. The crypts are localized at the intervillus region, and formed
as the result of epithelial invaginations towards the basolateral side
of the epithelium. Infancy is a critical period to establish the
proliferative potential of the crypts, and thus the maintenance of the
structural and functional homeostasis in the intestine. Rodent
studies have revealed that crypt structures form during the first few
days after birth, and continue to develop during the next several
weeks. Recently, Cummins et al. [1] found that crypt fission (also
called branching, which is a process of physiologic mechanism of
crypt reproduction) is present predominantly during infancy, but
not during later developmental stages, further supporting the
significance of infancy for crypt development.
Growth factors are known to be present in breast milk [2,3,4],
and have been investigated in their capacities to enhance intestinal
growth. Transforming growth factor alpha, hepatocyte growth
factor [5], and epidermal growth factor [6] are able to significantly
stimulate crypt cell proliferation as measured by 3H-thymidine
incorporation assay. Crypt cell migration and cell proliferation
increased after mucosal injury in rat crypt IEC-6 cell in response
to insulin like-growth factor 1 [7]. In addition, tyrosine
phosphorylation of MAPK, MAPK-dependent increase in p21
(waf1/cip1), c-Myc, and c-Fos expression were found to be
upstream events in growth factor induced crypt cell proliferation
[6,8,9]. This intricate cellular crosstalk occurred during intestinal
cell growth, and is likely to involve several signaling pathways
mediated via transcription factors, extracellular matrix compo-
nents, and cytokines. Understanding the molecular mechanisms
regulating crypt proliferation may help the discovery of more
targeted strategies to promote intestinal growth as well as defining
the pathologies of a number of human gastrointestinal diseases,
including infection, irritable bowel syndrome, and colorectal
cancer associated with aberrant patterns in crypt cell proliferation
[10,11].
MicroRNAs (miRNAs) are a new class of small non-coding RNAs
emerged over the past several years, functioning as critical
regulators of gene expression. MiRNAs are 19–25 nucleotides in
length, highly conserved across species, and have different
complementarity with their corresponding mRNAs. MiRNAs
negatively regulate gene expression post-transcriptionally by
repressing translation or targeting mRNA degradation [12].
MiRNAs have been shown to play crucial roles in biological
processes, including the cell cycle and apoptosis [13,14]. Our recent
data revealed that miR-30e is a downstream target of beta-catenin
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during intestinal crypt cell differentiation [15]; Hino et al. showed
that miR-194 expression was induced by HNF-1alpha during
intestinal epithelial cell differentiation [16], suggesting active roles
for miRNAs during intestinal development. Despite these findings,
very few mechanistic studies have been performed to examine
functional roles of miRNAs in intestinal cell proliferation.
The objective of this study was to use isolated mouse small
intestinal crypt cells to observe functional expression of miRNAs
during the IGF-1 induced intestinal crypt cell proliferation, and to
identify individual miRNAs associated signaling molecules in-
volved in this process.
Materials and Methods
Mouse intestinal crypt cell culture
This study complied with the Guide for the Use and Care of
Laboratory Animals and the protocol was approved by the
Institutional Animal Care and Use Committee at University of
California, Davis, which is accredited by the American Association
for the Accreditation of Laboratory Animal Care (AAALAC).
Virgin 5–6 weeks old C57BL/6 mice were obtained from Charles
River Laboratories and fed control chow diet upon arrival. Mice
were maintained in stainless-steel hanging cages on a 12:12-h
light-dark cycle. Female mice were mated overnight, and the day
pups were born were considered postnatal day (PD) 0. Animals
aged PD10 were killed by decapitation.
Small intestine crypt cell isolation was performed according to
the method of Sato et al. [17] with modifications. Briefly, small
intestine was quickly isolated and the attached fat was removed.
The longitudinally opened small intestine was washed with cold
16PBS (all PBS was DEPC treated, unless otherwise noted), then
transferred to a 50 ml tube with cold PBS. The intestine was
washed until the supernatant was clear. The intestine was further
washed with 2 mM EDTA in PBS at 4uC for 45 min. The small
intestine was resuspended with new PBS, supernatant was
discarded, this step was repeated and the crypt enriched portion
of fractions 2–4 was used.
The crypt fraction was diluted with Advanced DMEM/F12
(ADF) and centrifuged at 12006 g for 5 min. The pellets were
resuspended in 15 ml ADF and collected in a 50 ml falcon tube
after passing through a 70 mm cell strainer (Fisher). The tube was
centrifuged at 6006 g for 2 min to remove single cells. The ADF
wash was repeated 3 times. The cell pellets were resuspended with
crypt culture media (Advanced DMEM/F12, GlutaMax 1:100,
Hepes 10 mM, Penicillin/Streptomycin 1:100, N2 supplement
1:100, B27 supplement, retinoic acid free 1:50, mouse recombi-
nant EGF 50 ng/ml), mouse recombinant noggin 100 ng/ml,
human recombinant R-spondin1 500 ng/ml, and N-Acetylcyste-
ine 1 mM). The number of crypts was calculated using Trypan
Blue exclusion assay.
IGF-1 treatment
Crypt cells were seeded at 50% confluency per well in 6-well
plate prior to treatment with 20 ng/ml IGF-1 (R&D Systems), and
the control group was treated with 16 PBS alone. Cells were
collected as follows: 24 h after treatment for BrdU Cell
Proliferation ELISA (Roche) and immunoblotting analysis; total
RNAs were collected every 3 h during a 24 h treatment period for
miRNA analysis.
Cell culture
IEC-6 cells were maintained as described by Liao and
Lo¨nnerdal [15]. HEK293 cells were maintained as described in
[18].
miR-103 mimic or LNA inhibitor transfection was performed as
previousely described [18]. For immunoblotting analysis, IEC-6
cells were seeded at 50% confluency per well in 6-well plate the
day prior to transfection with 50 nM miR-103 inhibitor
(Dharmacon). Cells were collected 48 h after transfection; for
BrdU incorporation assay, IEC-6 cells were seeded at 50%
confluency per well in 96-well plate 6 h prior to transfection with
50 nM miR-103 mimic (Dharmacon); 24 h after transfection, the
cells were treated with 20 ng/ml IGF-1, and cell proliferation
assay was performed 24 h after IGF-1 treatment.
Bioinformatics analysis
The mature sequence of miR-103 (59-AGCAGCAUUGUA-
CAGGGCUAUGA-39) was retrieved from the miRBase Sequence
Database, release 14 (http://microrna.sanger.ac.uk/sequences/),
and mRNA 39UTRs of CCNE1, CDK2, and CREB1 from
human and mouse were aligned with miR-103 sequence using the
ClustalW program (http://www.ebi.ac.uk/Tools/clustalw/index.
html).
The miR-103 gene targets were predicted from the MicroCosm
Targets Version 5 (http://www.ebi.ac.uk/enright-srv/microcosm/
cgi-bin/targets/v5/search.pl), and the 1040 resulted genes were
loaded onto the Ingenuity Pathways Analysis software (IPA version
7.6, http://www.ingenuity.com). Core Analysis was performed to
examine biological networks potentially associated with these
miRNAs. Futhermore, Target Scan version 5.1 (www.targetscan.
org) was used to scan for seed matches between the miR-103 seed
region and the predicted gene.
MicroRNA array
RNA integrities were examined on Bioanalyzer for quality
control at the University of California, Davis Genome Center. For
analyzing miRNA expression, miRNA microarray was performed
at the J. David Gladstone Institute Genomics Core facility,
University of California, San Francisco (http://www.gladstone.
ucsf.edu/gladstone/php/?sitename = genomicscore).
300 ng of each sample was labeled with Cy5/Cy3 using
miRCURY LNA microRNA array Power Labeling kit (Exiqon).
Hybridization SureHyb chamber kit and Gasket slide kit (Agilent)
were used to hybridize the labeled RNA for 18 h to Exiqon
miRCURY LNA miRNA array V.11.0 (miRBase Sequence
Database, http://microrna.sanger.ac.uk/sequences, release 11.0).
This array contains 9360 probes, 3300 of which represent 825
human miRNAs with 4 duplicate probes per miRNA, additional
1400 probes for miRNA inmouse or rat and 472 probes for miRNA
in human/mouse viruses. In addition, there is a variety of control
and other probes: 1640 empty, 476 spike_control, 28 negative
controls, 12 U6-snRNA, 60 hsa_SNORD, 1728 miRPlus, 4
5SrRNA, and 240 Hy3. For each group, 3 arrays were run, and
1 array was dye swapped. Arrays were scanned on an Axon
GenePix 4000B scanner, andGPR files containing fluorescent ratios
(sample/control) were generated using GenePix Pro 6.0 software.
Vector construction
A 532 bp fragment of the human CCNE1 mRNA 39UTR
(corresponding to nt 1406–1937 of the Entrez PubMed transcript
BC035498) was PCR amplified from a pOTB7 vector containing
CCNE1 full length cDNA (Open Biosystems); a 1426 bp fragment
of the human CREB1 mRNA 39UTR (corresponding to nt 1180–
2606 of the Entrez PubMed transcript BC095407) was PCR
amplified from a pBluescriptR vector containing CREB1 full
length cDNA (Open Biosystems); The PCR products were cloned
into pGL3-control luciferase reporter vector (Promega) via an XbaI
restriction site, immediately downstream of the luciferase gene; a
Intestine Cell Grow Regulation
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38 bp fragment of the human CDK2 mRNA 39UTR (corre-
sponding to nt 1531–1568 of the Ensembl transcript BC093646)
was synthesized (Genscript Inc. USA), and the gene was then
directly annealed to pGL3-control luciferase reporter vector at the
XbaI restriction site.
A 530 bp fragment of the mouse CCNE1 mRNA 39UTR
(corresponding to nt 1426–1955 of the Entrez PubMed transcript
NM_007633.2) was PCR amplified from a pCMV-SPORT6.1
vector containing mouse CCNE1 full length cDNA (imaGenes); a
1160 bp fragment of mouse CDK2 mRNA 39UTR (corresponding
to nt 1227–2386 of the Entrez PubMed transcript BC005654) was
PCR amplified from pCMV-SPORT6 vector containing mouse
CDK2 full length cDNA (Open Biosystems); a 899 bp fragment of
mouse CREB1 mRNA 39UTR (corresponding to nt 1143–2041 of
the Entrez PubMed transcript BC021649) was PCR amplified from
pCMV-SPORT6 vector containing mouse CREB1 full length
cDNA (Open Biosystems). The PCR products were cloned into
pGL3-control luciferase reporter vector (Promega) via an XbaI
restriction site, immediately downstream of the luciferase gene.
Luciferase assay
For luciferase assays, HEK293 cells were seeded at 70%
confluency per well in 96-well plate 6 h prior to transfection with
4 ng/ml luciferase expression construct and 12.5–80 nM miR-103
mimic (Dharmacon). Mock transfected cells were transfected with
luciferase expression construct alone. cel-miR-67 (Dharmacon)
served as a negative control for miR-103 mimic. Luciferase activity
was measured 24 h after transfection using the Dual Glo
Luciferase Assay System (Promega), and pGL4.73[hRluc/SV40]
vector (Promega) served as internal control.
Real-time Q-PCR
Total RNA from cultured mouse small intestinal crypt cells was
isolated using miRNeasy Mini Kit (Qiangen) and diluted to 2 mg/
ml in DEPC-treated nuclease free water (Ambion Inc.).
For miR-103 assay, cDNA was generated from 2 mg RNA using
TaqManH MicroRNA Reverse Transcription Kit (Applied
Biosystems) according to the manufacturer’s protocol. The mature
miR-103 gene specific stem-loop RT primer for reverse transcrip-
tion was designed according to miRNAs sequences listed in the
Sanger miRBase (http://microrna.sanger.ac.uk/sequences/). The
pri-miR-103 assay kit was purchased from Applied Biosystems.
The primers used for b-actin were forward 59-ACTGCTCTGGC-
TCCTAGCAC-39, reverse 59-ACATCTGCTGGAAGGTG-
GAC-39. The RT reaction and PCR reaction were performed as
previously described [18].
Each sample was analyzed in triplicate and normalized to
snoRNA202 for mature miR-103 and b-actin for pri-miR-103 using
the following equation: DCtGENE=CtGENE-CtsnoRNA202/b-actin. The
fold change, relative to the control group was calculated using the
following equation: 2(DDCtGENE) where DDCtGENE=DCtGENE of
snoRNA202/b-actin - DCtGENE of each well.
Immunoblotting analysis
Mouse intestinal crypt cells before and after IGF1 treatment
were homogenized in RIPA buffer (25 mM Tris-HCl pH 7.6,
150 mM NaCl, 1% NP-40, 1% Sodium deoxycholate and 0.1%
SDS) containing 16 complete EDTA-free protease inhibitor
(Roche). 50 mg proteins were electrophoresed through 10%
polyacrylamide gel, transferred onto nitrocellulose membrane at
350 mA for 60 min, and blocked overnight in 16 PBS/0.1%
Tween-20 (PBST) with 5% non-fat milk at 4uC.
Bands were detected using Super Signal Femto chemilumines-
cent reagent (Pierce) and quantified using the Chemi-doc gel
quantification system (Bio-Rad). All data were normalized to
mouse b-actin.
Data analysis
GPR files were read into R/Bioconductor [19] using the marray
package. GenePix flagged spots were removed from subsequent
analysis, and only unflagged human, mouse and rat probes were
used for normalization and subsequent analysis. M (log2 ratios) of
Cy5 to Cy3 signals were calculated for each array, and normalized
by print tip loess normalization [20,21] using only unflagged spots.
For each miRNA with more than 1 unflagged probe, the median
of normalized M of the replicate probes was taken as its summary
value for the miRNA in each array. The summarized M of the
samples/array of each experiment was then used in moderated t-
statistics and p-value calculation using the limma package in R/
Bioconductor [22,23] with adjustment for false discovery rate
using the Benjamini-Hochberg method [24].
All other data were analyzed by Prism (PrismGraphPad Software).
The difference between treatment group and control were tested by
two-tailed Student’s t test. Data are shown as means6 SEM of three
independent experiments. Differences were considered significant
when P,0.05.
Results
IGF-1 stimulates proliferation of mouse small intestinal
crypt cells
By adapting the crypt culture protocol from Sato et al. [17], we
were able to isolate mouse small intestinal crypt cells. The cells
Figure 1. Mouse small intestinal crypt cells express PCNA. PCNA
expression was analyzed by immunoblotting. 50 mg total proteins from
extracted mouse small intestinal crypt cells and cultured rat intestinal
crypt cell line IEC-6 were loaded. PCNA was expressed in both cell types
and with significantly higher abundance in mouse small intestinal crypt
cells (P,0.01) than in IEC-6 cells. b-actin served as a loading control.
Values are means 6 SEM run in triplicates.
doi:10.1371/journal.pone.0012976.g001
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attach to the culture dish about 3 h after seeding. PCNA is highly
expressed in the isolated crypt cells (Figure 1), and rat crypt IEC-6
cells served as a reference for PCNA expression. During 24 h of
treatment, IGF-1 stimulated crypt cell proliferation rate
(100.0%637.1% vs 178.9%612.5%, P,0.05) by the BrdU
incorporation assay (Figure 2).
Identification of microRNAs differentially regulated
during IGF-1 stimulated crypt cell proliferation
We generated a microarray containing 1293 nonredundant
human, rodent, and virus miRNA species to determine expression
levels of mature miRNAs purified from mouse small intestinal
crypt cells before and after 20 ng/ml IGF-1 treatment. The raw
data are deposited in Gene Expression Omnibus (GEO), with
accession number GSE20133. Among all screened individual
miRNAs, 44 miRNAs were significantly regulated, including 18
significantly down-regulated, and 26 significantly up-regulated
upon IGF-1 treatment (Figure 3).
miR-103 is directly involved in IGF-1 stimulated mouse
intestinal cell proliferation
MA plot showed that miR-103 was the most substantially
reduced miRNA during IGF-1 stimulated crypt cell proliferation
(Mean log2 ratio of 21.176) (Figure 4A). Kinetic analysis by real-
time Q-PCR confirmed the presence of mature miR-103
Figure 2. IGF-1 stimulates mouse small intestinal crypt cell
proliferation. Crypt cells in 96-well plate were treated with 20 ng/ml
IGF-1; the control group was grown in the crypt cell growth medium
alone. After treatment for 24 h, rate of cell proliferation was measured
by Brdu incorporation assay. IGF-1 significantly stimulated proliferation
of the crypt cells (P,0.05). Values are means 6 SEM run in triplicates;
asterisks indicate significant differences between IGF-1 treatment and
control groups.
doi:10.1371/journal.pone.0012976.g002
Figure 3. Forty-four miRNAs were significantly correlated with mouse crypt cell proliferation upon IGF-1 treatment. Hierarchical
clustering analysis was performed using Euclidian distance. Each row represents relative levels of expression for a significantly regulated single
microRNA and each column represents the relative expression level of a single replicate relative to control (P,0.01). Colors on the figure represent
the scaled fold-change between samples within a gene. Control group was set to 0.
doi:10.1371/journal.pone.0012976.g003
Intestine Cell Grow Regulation
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12976
(Figure 4B) and pri-miR-103 (Figure 4C) in small intestinal crypt
cells, and also revealed that during the first 6 h of IGF-1
treatment, expression of mature miR-103 and pri-miR-103 was
rapidly reduced to 39% and 16% of initial levels, respectively
(P,0.01). Mature miR-103 then rebounded to 57% of the level
prior to treatment (P,0.01), while pri-miR-103 expression was
maintained at ,25% of the level prior to treatment (P,0.01).
Furthermore, IGF-1 stimulated cell proliferation in IEC-6 cells
was significantly inhibited by overexpression of miR-103
(211%617% vs 140%65%, P,0.05) (Figure 5).
Identification of miR-103 target genes in mouse small
intestinal crypt cells
We retrieved the predicted 1040 target genes of miR-103 from
the miRBase target database, and loaded them onto the Ingenuity
Pathway Analysis software (IPA version 7.6). We were then able to
identify cellular pathways affected by IGF-1 treatment of crypt
cells. Interestingly, among the 5 top ranked molecular networks,
‘‘cell cycle, cell death’’ had the highest score; Remarkably, among
the 5 top ranked biofunctions, ‘‘cellular growth and proliferation’’
involved 147 molecules, 1/3 of the total number of molecules.
CCNE1 as a predicted target was the top ranked molecule with
the lowest exponential value of 8.49E-09. We then used Target
Scan to screen the target genes, focusing on the cell cycle and cell
death regulation. Importantly, we identified CCNE1, CDK2, and
CREB1 as critical components during the cell cycle process. We
then manually aligned the mRNA 39UTR and the miR-103 seed
region (Figure 6A), which were found to be highly matched for
both human and mouse genes.
We explored whether miR-103 could affect the identified gene
targets through interaction with the mRNA 39UTR. In HEK293
cells, co-transfection with miR-103 mimic could repress the
luciferase activity generated by luciferase vectors containing the
mRNA 39UTRs of CCNE1, CDK2, CREB1 of human (Figure 6B)
and mouse (Figure 6C) origin in a dose dependent manner, clearly
indicating direct binding between the miRNA sequence and the
genes. In comparison, the negative control miRNA, cel-miR-67,
did not result in any significant reduction of luciferase activity. As
Figure 4. miR-103 expression analysis in IGF-1 stimulated mouse small intestinal crypt cells. (A) microrarray analysis of total miRNA
expression in crypt cells after stimulation with IGF-1 for 24 h. The MA plot shows the averaged and background-subtracted fold change on a log2
scale (Y axis) and average expression intensity (X axis) of each miRNA on both channels for Cy-3 labeled control and Cy-5 labeled treated cells and
their dye-swaps. Each dot or triangle represents one miRNA probe. Arrow indicates miR-103 probe, which is 44.26% of relative control intensity over
the course of 24 h. (B, C) real-time Q-PCR analysis of mature miR-103 (B) and pri-miR-103 expression (C) during 24 h IGF-1 treatment in crypt cells.
Data were normalized to snoRNA-202 levels for mature miR-103 and b-actin for pri-miR-103. Values are means6 SEM run in triplicates, letters indicate
significant differences between time points.
doi:10.1371/journal.pone.0012976.g004
Figure 5. miR-103 is directly involved in IGF-1 stimulated crypt
cell proliferation. IEC-6 cells in 96-well plate were transfected with
50 nM miR-103 mimic before treated with 20 ng/ml IGF-1. The control
group was cultured in growth media or treated with IGF-1 alone. Cell
proliferation was measured by BrdU incorporation assay. Values are
means 6 SEM run in triplicates. Letters indicate significant differences
between IGF-1 treatment and control groups.
doi:10.1371/journal.pone.0012976.g005
Intestine Cell Grow Regulation
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expected, in IEC-6 cells, miR-103 knock down by a LNA
oligonucleotide resulted in marked up-regulation of the aformen-
tioned gene products (Figure 6D) (1.4360.13 vs 1.0060.26 for
CCNE1, P,0.05; 1.6360.13 vs 1.0060.13 for CDK2, P,0.01;
1.6260.10 vs 1.0060.25 for CREB1, P,0.05), presumably
because of a decrease in miR-103 mediated mRNA inhibition or
degradation.
CCNE1, CDK2, and CREB1 are directly involved in mouse
intestinal cell proliferation stimulated by IGF-1
To examine whether the miR-103 targets are involved in IGF-1
stimulated mouse intestinal cell proliferation, immunoblotting
analyses were performed on the crypt cells before and after IGF-1
treatment. As shown in Figure 7A, IGF-1 significantly upregulated
CCNE1, CDK2, and CREB1 protein expression. In addition,
IGF-1 stimulated cell proliferation of IEC-6 cells was significantly
inhibited by siRNA of these genes (Figure 7B).
Discussion
IGF-1 is a 7.5 kD polypeptide consisting of 70 amino acids, and
found to be present in human milk [25]. In the gastrointestinal
tract, the IGF-1 signaling pathway is initiated by the interaction
between cell surface IGF-1 receptors, which are most abundant at
the basolateral side of the crypt. IGF-1 is a potent stimulator of
intestinal crypt cellular growth, and has been used as a therapeutic
approach to facilitate the intestinal repair process in gastrointes-
tinal disorders, such as enteritis and IBD [26]. However, few
investigations have examined the molecules and signaling
pathways involved in the crypt growth under normal conditions.
MiRNAs are a class of small regulatory molecules which critically
affect mRNA translation in a sequence specific manner. It has
been shown that miRNAs control the expression of genes related
to cellular development; however, to date miRNA expression in
small intestinal proliferative unit crypts has not been studied and
its role in crypt proliferation remains to be determined. In this
Figure 6. CCNE1, CDK2, and CREB1 are direct targets of miR-103 in mouse small intestinal crypt cells during IGF-1 stimulation. (A)
sequence alignment between miR-103 seed region and the seed matches on CCNE1, CDK2, and CREB1 mRNA 39UTR region. The analyses were
performed using the miRBase target database. The line indicates conserved seed match (A–T, C–G) in human and mouse, whereas the dot indicates
seed match in one of the two species. (B, C) miR-103 directly binds and represses CCNE1, CDK2, and CREB1 mRNA through 39UTR. pGL3-control
luciferase vectors containing the mRNA 39UTR of respective genes of human (B) or mouse (C) origin were co-transfected with the indicated amount of
miR-103 mimic in HEK293 cells, and luciferase activity was analyzed 24 h post-transfection. The structurally unrelated miRNA cel-miR-67 served as
negtive control. (D) CCNE1, CDK2, and CREB1 protein expression were examined in IEC-6 cells after transfection with 50 nM miR-103 inhibitor.
Scramble (scr) miRNA transfected cells served as control. Values are means 6 SEM run in triplicates, and letters indicate significant differences
between treatment groups and control.
doi:10.1371/journal.pone.0012976.g006
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study, we successfully cultured mouse intestinal crypt cells during a
24 h period and confirmed targeting of the CREB1 transcription
factor, and CCNE1/CDK2 by miR-103 during cell cycle
progression, implicating a role for miRNAs in intestinal growth.
There are some limited reports on intestinal epithelial miRNA
expression. Takada et al. [27] showed high abundance of miR-143
and miR-194 in mouse small intestine and Hino et al. [16,28]
further showed induction of miR-194 by HNF-1 during
differentiation of intestinal epithelial Caco-2 cells. We used a
sensitive model for stimulating intestinal crypt cell proliferation by
a growth factor, and obtained not only the first extensive mouse
intestinal crypt cell miRNA profiles, but also the differentially
expressed miRNA species during cell proliferation. Our screening
identified a total of 233 microRNAs from mouse small intestinal
crypt cells, and showed that crypt cells have dramatically different
miRNA profiles upon IGF-1 stimulation. We performed real-time
Q-PCR analysis to monitor the expression of some of these
intestinal miRNAs, from which we confirmed two down-regulated
miRNAs, miR-103 and miR-17. No statistically significant
regulations were found for miR-143 or miR-194.
The miR-103 family is found in 23 species, and comprised of 2
isoforms: miR-103-1 located on human chromosome 5q34 and
miR-103-2 located on human chromosome 20p13 [29,30,31].
Interestingly, the long arm of chromosome 5 (5q) is a region
associated with the risk of developing the gastrointestinal disorders
of Crohn’s disease and IBS (Genetics Home Reference, http://
ghr.nlm.nih.gov/). miR-103 has also been shown to stimulate
adipogenesis that accelerates fat cell proliferation, and is down-
regulated in obesity [32].
Remarkably, among predicted gene targets for miR-17 were
WEE1, CCNA1, E2F5, MCM4, RAD51, and CABLES1, which
are critically involved in cell cycle progression. For example,
WEE1 is a key cell cycle regulator by the inhibiting Cdc2 at the
G2/M transition, coordinating cell cycle and cell sizes; a decrease
in WEE1 leads to smaller daughter cells and an increase in WEE1
prevents cells from entering mitosis [33]. CCNA1 belongs to the
cyclin family, and binds to important cell cycle regulators such as
E2F, Rb, CDK2 and p21, but its abundance in the intestine is low
[34]. Ingenuity Pathway Core Analysis of miR-17 showed that cell
cycle, DNA replication, recombination, repair, and cancer scored
34, being the second highest identified network. The G2/M
transition of the cell cycle had a P-value of 7.81-E02, being one of
the most significantly affected cellular processes.
In this report, we examined whether miR-103 can bind and
affect the predicted target mRNAs through mRNA 39UTR
interactions. Accordingly the full-length mRNA 39UTRs of
CCNE1, CDK2 and CREB1 were individually cloned into a
reporter vector, downstream of a firefly luciferase cDNA. The
human homologue of the mRNA 39UTR was used, and
computational approaches (Figure 6A) predicted that there is an
8-mer seed match between miR-103 and mouse CREB1/CDK2,
while there is a 7-mer seed match between miR-103 and the
human homologue; there is a 7-mer seed match between miR-103
and mouse CCNE1 mRNA 39UTR, and an 8-mer seed match
between miR-103 and the human homologue. As seen in
Figures 6B and Figure 6C, in HEK293 cells, all vectors containing
the 39UTRs of CCNE1, CDK2, and CREB1 displayed dose-
dependent light emission reduction upon co-transfection with
increasing miR-103 mimic, indicating the presence of a direct
binding site for miR-103. The CCNE1 vector displayed a more
sensitive response to the miR-103 mimic, possibly because of
higher percentage seed match to the human homologue.
Immunoblotting of IEC-6 cells demonstrated that CCNE1,
CDK2, CREB1 are induced at the protein level upon miR-103
inhibition, further supporting an effect of miR-103 regulation on
these genes.
CCNE1 is a member of the cyclin family which is characterized
by a dramatic periodicity in protein expression throughout the cell
cycle [35]. CDK2, CDK4, and CDK6 are the active kinases
controlling G1/S transition in mammals. CCNE1 forms a
complex with CDK2 and functions as a serine/threonine kinase
regulatory subunit, which is indispensible for cell cycle G1/S
progression, peaking at the G1-S phase boundary. [36,37]. Direct
functional evidence for CCNE1 is provided by the microinjection
Figure 7. CCNE1, CDK2, and CREB1 are directly involved in IGF-1 stimulated crypt cell proliferation. (A) immunoblotting analyses of
CCNE1, CDK2, and CREB1 protein in mouse small intestinal crypt cells with or without IGF-1 treatment for 24 h. Data were normalized to b-actin.
Values are means 6 SEM run in triplicates, asterisks indicate significant differences between control and IGF-1 treated cells. (B) CCNE1, CDK2, and
CREB1 proteins were knocked-down by siRNA in IEC-6 cells before treated with IGF-1. Cell proliferation was measured 24 h after IGF-1 treatment.
Values are means 6 SEM run in triplicates, letters indicate significant differences between time points.
doi:10.1371/journal.pone.0012976.g007
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of anti-cyclin E antibodies into fibroblasts during G1 which
resulted in cell cycle arrest [38]. It should be noted that other
microRNAs potentially regulating CCNE1 protein expression
were also significantly changed, including down-regulation of
miR-141, miR-16, miR-15a, miR-352, miR-15b and up-regula-
tion of miR-518e, miR-29a, miR-192, and miR-29b, implicating a
regulatory network fine-tuning the cell cycle checkpoints.
Among the mRNA targets of miR-103 was also the transcrip-
tion factor CREB1 gene, which binds as a homodimer to cAMP
responsive elements within the DNA sequence [39]. Activation of
CREB1 induces the early response genes, and late response genes
during the early G1 phase of cell cycle [40,41]. Remarkably, upon
IGF-1 treatment, CREB1 also showed up-regulation in the
TranSignal Cell Growth Protein DNA Array (Panomics Inc.),
which includes AP1, c-Myb, CREB (miRBase predicted miR-103
target), E2F-1, EGR, Ets, FKHR, Myc-Max, NE-E1 (YY1), NF-
kB(miRBase predicted miR-103 target), OCT-1, p53, Pax-2, Pax-
3, Pax-6, PPAR-c, Smad SBE, Sp1, SRE, and Stat3. In
immunoblotting analysis, the phosphorylated-CREB1 protein
was also up-regulated, indicating functional activation during
miR-103 inhibition.
An improved understanding of miRNA signatures during
intestinal epithelial cell proliferation should ultimately lead to the
discovery of drugs better suited to treat diseases due to abberant
cellular growth, such as inflammatory diseases and cancer. The
present study determined the global microRNA expression in
mouse crypt cells, and confirmed functional aspects of miR-103,
which could be a suitable candidate for developing novel
therapeutic interventions.
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